Madrigal Pharmaceuticals, Inc. (MDGL)
541.08
-1.53
(-0.28%)
USD |
NASDAQ |
Sep 04, 16:00
540.70
-0.38
(-0.07%)
Pre-Market: 20:00
Madrigal Pharmaceuticals SG&A Expense (TTM) : 1.007B for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.007B |
| March 31, 2026 | 914.47M |
| December 31, 2025 | 813.83M |
| September 30, 2025 | 715.08M |
| June 30, 2025 | 613.54M |
| March 31, 2025 | 522.13M |
| December 31, 2024 | 435.06M |
| September 30, 2024 | 340.37M |
| June 30, 2024 | 260.37M |
| March 31, 2024 | 172.76M |
| December 31, 2023 | 108.15M |
| September 30, 2023 | 76.17M |
| June 30, 2023 | 60.72M |
| March 31, 2023 | 54.65M |
| December 31, 2022 | 48.13M |
| September 30, 2022 | 45.28M |
| June 30, 2022 | 41.43M |
| March 31, 2022 | 39.77M |
| December 31, 2021 | 37.32M |
| September 30, 2021 | 31.73M |
| June 30, 2021 | 28.94M |
| March 31, 2021 | 24.47M |
| December 31, 2020 | 21.86M |
| September 30, 2020 | 20.78M |
| June 30, 2020 | 20.04M |
| Date | Value |
|---|---|
| March 31, 2020 | 21.51M |
| December 31, 2019 | 22.65M |
| September 30, 2019 | 23.19M |
| June 30, 2019 | 23.56M |
| March 31, 2019 | 19.17M |
| December 31, 2018 | 15.29M |
| September 30, 2018 | 12.11M |
| June 30, 2018 | 8.942M |
| March 31, 2018 | 7.848M |
| December 31, 2017 | 7.672M |
| September 30, 2017 | 7.505M |
| June 30, 2017 | 11.84M |
| March 31, 2017 | 10.76M |
| December 31, 2016 | 9.290M |
| September 30, 2016 | 7.204M |
| June 30, 2016 | 1.116M |
| March 31, 2016 | 3.692M |
| December 31, 2015 | 7.620M |
| September 30, 2015 | 11.72M |
| June 30, 2015 | 14.76M |
| March 31, 2015 | 14.57M |
| December 31, 2014 | 15.75M |
| September 30, 2014 | 14.97M |
| June 30, 2014 | 15.90M |
| March 31, 2014 | 17.14M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Exelixis, Inc. | 533.92M |
| United Therapeutics Corp. | 644.60M |
| Karyopharm Therapeutics, Inc. | 101.98M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |